TSLA'S 2024 year has been a glorious one after surging 2x its valuation from 200 area on Q3 of 2024 to reach a parabolic ATH high of 485.
From there on, the stock has spiraled down -- since TRUMP inauguration.
Slashing half of its market cap from a 1.5T+ company to just 700B. Price suffered most on the market bloodbath from its ATH of 480 back to tappin its pre-surge base zone at 200 levels.
Now, things has become more or less calm. And red days has become saturated hinting of possible reversal play to the upside.
Significant net longs has been registered this past few days conveying heavy accumulation at the current price range of 200.
A double bottom has been spotted on our diagram showing a strong support of the price line.
Current price range is an ideal seeding zone for trade entries.
A rare bargain opportunity for that growth prospect -- and a retap of its glory days back at peak levels.
Spotted at 230.
Target ATH levels at 480.
TAYOR. Trade safely.
From there on, the stock has spiraled down -- since TRUMP inauguration.
Slashing half of its market cap from a 1.5T+ company to just 700B. Price suffered most on the market bloodbath from its ATH of 480 back to tappin its pre-surge base zone at 200 levels.
Now, things has become more or less calm. And red days has become saturated hinting of possible reversal play to the upside.
Significant net longs has been registered this past few days conveying heavy accumulation at the current price range of 200.
A double bottom has been spotted on our diagram showing a strong support of the price line.
Current price range is an ideal seeding zone for trade entries.
A rare bargain opportunity for that growth prospect -- and a retap of its glory days back at peak levels.
Spotted at 230.
Target ATH levels at 480.
TAYOR. Trade safely.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.